Payment overview · 2025
General Payments
$434.45
20 reported records · 14 companies
Healthcare provider profile · identity verified
Nehal T Patel, MD
Allopathic & Osteopathic Physicians|Family Medicine · BECKLEY, WV · NPI 1750686283
Verified facts
What the public records show
CMS Open Payments records show Nehal T Patel, MD received $434.45 in general payments during 2025 across 20 reported records.
Amgen Inc. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $84.05 | 19.4% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.99 | 13.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.30 | 10.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.15 | 7.6% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $29.28 | 6.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.10 | 6.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.62 | 5.7% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.34 | 5.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.79 | 5.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.57 | 4.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.46 | 4.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.47 | 3.6% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $15.11 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.22 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $434.45 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $68.84 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $68.84 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $59.99 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.15 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $29.28 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.10 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.10 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 177 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
133 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 150 |
| Levothyroxine Sodium | Levothyroxine Sodium | 467 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 434 | 139 |
| Metoprolol Succinate | Metoprolol Succinate | 346 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 299 | 106 |
| Gabapentin | Gabapentin | 230 | 48 |
| Omeprazole | Omeprazole | 222 | 75 |
| Montelukast Sodium | Montelukast Sodium | 206 | 67 |
| Lisinopril | Lisinopril | 205 | 62 |
| Furosemide | Furosemide | 196 | 72 |
| Tramadol Hcl | Tramadol Hcl | 195 | 46 |
| Eliquis | Apixaban | 177 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 43 |
| Famotidine | Famotidine | 140 | 50 |
| Metformin Hcl | Metformin Hcl | 138 | 43 |
| Alprazolam | Alprazolam | 134 | 29 |
| Ozempic | Semaglutide | 133 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 40 |
| Potassium Chloride | Potassium Chloride | 115 | 41 |
| Losartan Potassium | Losartan Potassium | 112 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 107 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 27 |
| Lorazepam | Lorazepam | 104 | 22 |
| Methylprednisolone | Methylprednisolone | 104 | 89 |
| Simvastatin | Simvastatin | 100 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 29 |
| Azithromycin | Azithromycin | 93 | 75 |
| Glipizide | Glipizide | 89 | 23 |
| Trazodone Hcl | Trazodone Hcl | 88 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 26 |
| Meloxicam | Meloxicam | 78 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 37 |
| Pregabalin | Pregabalin | 76 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 75 | 63 |
| Donepezil Hcl | Donepezil Hcl | 74 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 19 |
| Sertraline Hcl | Sertraline Hcl | 67 | 18 |
| Allopurinol | Allopurinol | 65 | 19 |
| Alendronate Sodium | Alendronate Sodium | 62 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 53 |
| Levofloxacin | Levofloxacin | 61 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 17 |
| Buspirone Hcl | Buspirone Hcl | 58 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 22 |
| Mounjaro | Tirzepatide | 57 | 11 |
| Spironolactone | Spironolactone | 54 | 21 |
| Diazepam | Diazepam | 52 | suppressed |
| Cephalexin | Cephalexin | 51 | 40 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 19 |
| Mirtazapine | Mirtazapine | 49 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Carvedilol | Carvedilol | 46 | 18 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 12 |
| Finasteride | Finasteride | 41 | 13 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Tradjenta | Linagliptin | 40 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | 11 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 15 |
| Cefdinir | Cefdinir | 35 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Valsartan | Valsartan | 32 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 11 |
| Ondansetron Odt | Ondansetron | 31 | 19 |
| Naproxen | Naproxen | 30 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Torsemide | Torsemide | 28 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 27 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Lactulose | Lactulose | 26 | 13 |
| Bupropion Xl | Bupropion Hcl | 25 | 11 |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 15 |
| Baclofen | Baclofen | 22 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 16 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Nystatin | Nystatin | 17 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $434.45 · 20 records | Amgen Inc. | BREZTRI, Cologuard Collection Kit, ELIQUIS, EVENITY, Fluad, Flucelvax, JARDIANCE, JOURNAVX, NURTEC ODT, OTEZLA, PROLIA, QULIPTA, QUTENZA, REPATHA, UBRELVY, VIVITROL, VYNDAMAX, Veozah, WATCHMAN Access System, Wegovy, ZENPEP | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error